BiondVax Pharmaceuticals (NASDAQ:BVXV) Receives New Coverage from Analysts at assumed coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) in a research note issued on Friday. The brokerage set a “sell” rating on the stock.

Separately, Aegis began coverage on shares of BiondVax Pharmaceuticals in a research report on Wednesday, January 26th. They set a “buy” rating and a $7.00 price objective on the stock.

NASDAQ BVXV opened at $1.20 on Friday. The company has a 50 day simple moving average of $1.46 and a 200-day simple moving average of $1.66. The company has a debt-to-equity ratio of 2.71, a current ratio of 7.64 and a quick ratio of 7.64. The firm has a market capitalization of $13.62 million, a price-to-earnings ratio of -1.58 and a beta of 2.52. BiondVax Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $4.19.

BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) last posted its quarterly earnings results on Monday, March 28th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.18). On average, analysts predict that BiondVax Pharmaceuticals will post -0.41 EPS for the current year.

Several institutional investors have recently modified their holdings of BVXV. Millennium Management LLC bought a new stake in shares of BiondVax Pharmaceuticals during the 2nd quarter worth $33,000. Citadel Advisors LLC acquired a new position in BiondVax Pharmaceuticals during the 3rd quarter worth $40,000. Envestnet Asset Management Inc. bought a new stake in BiondVax Pharmaceuticals during the fourth quarter valued at about $118,000. Finally, Morgan Stanley boosted its holdings in BiondVax Pharmaceuticals by 24.3% during the second quarter. Morgan Stanley now owns 51,592 shares of the company’s stock valued at $148,000 after acquiring an additional 10,071 shares during the period. Institutional investors and hedge funds own 2.96% of the company’s stock.

BiondVax Pharmaceuticals Company Profile (Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

Read More

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with's FREE daily email newsletter.